Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage of the disease. Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of AD. In vivo brain 2-[(18)F]fluoro-2-Deoxy-D-glucose-positron emission tomography (FDG-PET) imaging demonstrates consistent and progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This review will give an overview of FDG-PET results in individuals at risk for developing dementia, including: presymptomatic individuals carrying mutations responsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) epsilon4 allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family history of AD; subjects with subjective memory complaints; and normal elderly followed longitudinally until they expressed the clinical symptoms and received post-mortem confirmation of AD. Finally, we will discuss the potential to combine different PET tracers and CSF markers of pathology to improve the early detection of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Pellerin, L., & Magistretti, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10625 · Cited by 2,927 · cited 2×
“that coupling between energy metabolism and neuronal activity may also be achieved through astrocytic uptake of glucose and lactate shuttling to neurons.(33)”
BackgroundAlzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 3×
“The regional patterns of CMRglc reductions in MCI are milder and more variable than those found in AD and correspond to variations in the patterns of cognitive and behavioral abnormalities in individual patients.62,63 Importantly, FDG-PET studies in MCI showed that hippocampal hypometabolism is a consistent feature of…”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Life and Death of Neurons in the Aging Brain
Morrison, J. H., & Hof, P. R. (1997) · Science · doi:10.1126/science.278.5337.412 · Cited by 1,344
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Relationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 1×
“mal subjects who later declined experienced greater rates of hippocampal, PCC and temporal cortex CMRglc reductions, as compared to non-declining subjects.(69)”
ResultInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · cited 3×
“Fagan recently reported that CSF Aβ42 reductions are associated with PIB evidence for deposition, but that the relationship is bimodal rather than linear.(93) CSF Aβ42 reductions predict decline from MCI to dementia(106) and from CDR=0 to CDR>0 when combined with T-tau or P-tau181.”
BackgroundResultInfluentialImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 2×
“At this early stage of development, PIB-PET has also been shown to facilitate an improved differential diagnosis of different dementias.(92,95) Although, a recent study suggested that PIB may not be specific for dense, classical plaques.”
BackgroundFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“These CMRglc reductions are considered the earliest brain abnormalities yet found in living persons at risk for AD.(77)”
BackgroundThe neural basis of functional brain imaging signals
Attwell, D., & Iadecola, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02264-6 · Cited by 957
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD
Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Tangalos, E. G., & Kokmen, E. (2000) · Neurology · doi:10.1212/wnl.55.4.484 · Cited by 937
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 3×
“The available longitudinal data show Aβ42 levels decrease in AD, but the magnitude of change has limited diagnostic value.115,127 The background effects of aging on CSF turnover and Aβ production and clearance are poorly understood.128-130 Peskind et al.131 recently showed that CSF Aβ42 reductions were increasingly fo…”
BackgroundDiscrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832
RELATION BETWEEN PHYSIOLOGICAL FUNCTION AND ENERGY METABOLISM IN THE CENTRAL NERVOUS SYSTEM
Sokoloff, L. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb03919.x · Cited by 807 · cited 2×
“Thus, glucose metabolism can be interpreted as an index of synaptic functioning and density.(27,29-31) A recent animal study using FDG-PET showed a significant correlation between CMRglc in vivo and levels of synaptophysin, a marker of synaptic density, assessed at post-mortem.”
BackgroundCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Praticò, D., Uryu, K., Leight, S., Trojanoswki, J. Q., & Lee, V. M.-Y. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04183.2001 · Cited by 777
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · cited 1×
“However, reports about CSF X-tau levels in normal aging are limited and contradictory; some show age-related elevations in T-tau(110) and others do not.(111,112) Our adult lifespan data shows age-related increases after age 60 for both Ptau231 and T-tau, and both demonstrate additive ε4 related effects.”
BackgroundArriagada, P. V., Marzloff, K., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.9.1681 · Cited by 638
de Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629 · cited 5×
“FDG-PET studies in MCI showed that hippocampal hypometabolism is a consistent feature of MCI patients regardless of the neuropsychological profile.(49,50,55,61) Studies have shown”
BackgroundResultSelf-citationSmall, G. W. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520360056039 · Cited by 604
Morris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Hippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548 · cited 2×
“FDG-PET studies in MCI showed that hippocampal hypometabolism is a consistent feature of MCI patients regardless of the neuropsychological profile.(49,50,55,61) Studies have shown”
BackgroundSelf-citationAlexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
Geerlings, M. I., Jonker, C., Bouter, L. M., Adèr, H. J., & Schmand, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.531 · Cited by 487 · cited 1×
“these complaints represent a preclinical sign of incipient dementia.(80) We recently published an FDG-PET study examining CMRglc in cognitively normal individuals with and without SMC.”
BackgroundReiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467 · cited 3×
“There is evidence in middle-age ApoE-4 carriers that the metabolic reductions are progressive and correlate with reductions in cognitive performance.(73,76) One study showed a 25% decline in CMRglc over an interval of 2 years in cognitively normal persons carrying two ApoE-4 alleles.”
BackgroundBraak, H., & Braak, E. (1996) · Acta Neuropathologica · doi:10.1007/s004010050508 · Cited by 406
Risk of Dementia Among White and African American Relatives of Patients With Alzheimer Disease
Green, R. C. (2002) · JAMA · doi:10.1001/jama.287.3.329 · Cited by 391
Hippocampal hypometabolism predicts cognitive decline from normal aging
Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., Laska, E., Rusinek, H., & de Leon, M. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.008 · Cited by 360
Self-citationKanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G. (2007) · Brain · doi:10.1093/brain/awm191 · Cited by 302
Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.-O., Winblad, B., Valind, S., & Nordberg, A. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00045 · Cited by 302
EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS
De Leon, M., George, A., Stylopoulos, L., Smith, G., & Miller, D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90911-2 · Cited by 284
Rusinek, H., De Santi, S., Frid, D., Tsui, W.-H., Tarshish, C. Y., Convit, A., & de Leon, M. J. (2003) · Radiology · doi:10.1148/radiol.2293021299 · Cited by 281
Self-citationHippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
Reiman, E. M., Uecker, A., Caselli, R. J., Lewis, S., Bandy, D., De Leon, M. J., De Santi, S., Convit, A., Osborne, D., Weaver, A., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440226 · Cited by 266
Kennedy, A. M., Frackowiak, R. S. J., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J., & Rossor, M. N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11270-7 · Cited by 250 · cited 3×
“Several FDG-PET studies examining presymptomatic FAD have shown parieto-temporal, posterior cingulate, and frontal cortex hypometabolism in most FAD cases, as compared to age-matched controls.46,47 A study by Kennedy et al.47 showed that whole-brain CMRglc in presymptomatic FAD individuals is intermediate between cont…”
BackgroundResultMosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
Self-citationCerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease
Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223 · cited 2×
“ApoE is specifically thought to maintain neuronal homeostasis by transporting lipids such as cholesterol and phospholipids, which are responsible for neuronal plasticity, throughout the central nervous system.(72) ApoE also provides lipids necessary for the repair of damaged nerve cell membranes.”
BackgroundResultBrain imaging evidence of preclinical Alzheimer's disease in normal aging
Jagust, W., Gitcho, A., Sun, F., Kuczynski, B., Mungas, D., & Haan, M. (2006) · Annals of Neurology · doi:10.1002/ana.20799 · Cited by 222 · cited 2×
“The results showed that baseline CMRglc reductions in the angular gyri, left mid-temporal gyrus, and left middle frontal gyrus predicted rate of change on the MMSE, and were associated with faster cognitive decline.(68)”
BackgroundResultRocher, A. B., Chapon, F., Blaizot, X., Baron, J.-C., & Chavoix, C. (2003) · NeuroImage · doi:10.1016/j.neuroimage.2003.07.002 · Cited by 204
Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., Pirraglia, E., Tsui, W., De Santi, S., & de Leon, M. J. (2009) · Neurology · doi:10.1212/01.wnl.0000333247.51383.43 · Cited by 188
Self-citationCerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
Arai, H., Morikawa, Y.-I., Higuchi, M., Matsui, T., Clark, C. M., Miura, M., Machida, N., Lee, V. M.-Y., Trojanowski, J. Q., & Sasaki, H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6908 · Cited by 159 · cited 1×
“The T-tau level is not specific for AD, as CSF T-tau levels are also elevated in other neurodegenerative diseases.(114,115) In acute stroke, the T-tau, but not the P-tau181 levels, were increased and later returned to normal.”
BackgroundCSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
a, S. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90048-6 · Cited by 148 · cited 1×
“, patients with selective deficits in attention and language(51)) who show either an absence of cortical hypometabolism or hypometabolism in brain regions including, but not restricted to the anterior cingulate and parieto-temporal cortices.(49,55,61,64,65) In contrast, amnestic MCI patients more con-”
BackgroundParnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., & Hulstaert, F. (2001) · Neurological Sciences · doi:10.1007/s100720170055 · Cited by 141
Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C., Raskind, M. A., Schellenberg, G. D., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.936 · Cited by 131 · cited 2×
“Peskind et al.(131) recently showed that CSF Aβ42 reductions were increasingly found with old age and detected at younger ages in ε4 carriers, and our data confirm that observation.”
ResultFarrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Enhanced brain levels of 8,12- iso -iPF 2α -VI differentiate AD from frontotemporal dementia
Yao, Y., Zhukareva, V., Sung, S., Clark, C. M., Rokach, J., Lee, V. M.-Y., Trojanowski, J. Q., & Praticò, D. (2003) · Neurology · doi:10.1212/01.wnl.0000070185.02546.5d · Cited by 86
Cited by
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639
“Reductions in regional cerebral glucose metabolic rate (CMRglu) as measured by fludeoxyglucose F 18–positron emission tomography (FDG-PET) are also associated with increased AD risk and can be observed years before dementia onset.(2,3) A recent large study comparing FDGPET patterns in cognitively normal adults For edi…”
BackgroundDiabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Hazlett, H. C., Poe, M. D., Gerig, G., Styner, M., Chappell, C., Smith, R. G., Vachet, C., & Piven, J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.39 · Cited by 481
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
Diabetes drugs in the fight against Alzheimer's disease
Boccardi, V., Murasecco, I., & Mecocci, P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100936 · Cited by 142
Metadata
- Authors
- Mistur, R., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J.
- Venue
- Journal of Clinical Neurology
- Publisher
- XMLink
- Published
- 2009
- Volume
- 5
- Issue
- 4
- Pages
- 153
- ISSN
- 1738-6586 (ISSN-L)
- OpenAlex
- W2126015535
- Cited by
- 93
- References
- 60
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.